Table 2. Patient treatment history.
| Patient number | Date entered study | Treated? | TTT (yrs) | Received RTX | Drug regimen 1 | Drug regimen 2 |
|---|---|---|---|---|---|---|
| 1 | 7-13-11 | No | 4.5 | NA | NA | NA |
| 2 | 10-15-07 | Yes | 17.4 | Yes | 2015; IR (PR) | NA |
| 3 | 8-8-13 | No | 3.1 | NA | NA | NA |
| 4 | 10-7-09 | No | 7.3 | NA | NA | NA |
| 5 | 6-9-14 | Yes | 1.9 | No | 2015; Ob/CMB (CR) | NA |
| 6 | 12-15-10 | Yes | 6.6 | No | 2016; I (PR) | NA |
| 7 | 1-5-11 | No | 5.2 | NA | NA | NA |
| 8 | 11-28-07 | Yes | 6.0 | Yes | 2006; CMB (NR) | 2015; BR (CR) |
| 9 | 3-4-15 | No | 1.5 | NA | NA | NA |
| 10 | 3-3-10 | Yes | 5.5 | Yes | 2015; IR (PR) | NA |
| 11 | 1-5-15 | Yes | 4.1 | Yes | 2015; BR (PR) | 2015; I (PR) |
Abbreviations are: TTT, time-to-treatment (TTT), PR, Partial remission, CR, complete remission, NR, no response, IR, ibrutinib + rituximab; Ob/CMB, obinutuzumab + chlorambucil; I, ibrutinib; FCR, fludarabine + cyclophosphamide + rituximab; BR, bendamustine + rituximab. NA signifies not applicable.